Buscar
Mostrando ítems 1-6 de 6
Oral anticoagulation in octogenarians with atrial fibrillation
(Elsevier, 2016-08-08)
[Abstract] Background.
Vitamin K antagonists (VKAs) are still largely employed, even in nonvalvular atrial fibrillation (AF). Our aim was to study the clinical profile of octogenarians treated with oral anticoagulation ...
Do physicians correctly calculate thromboembolic risk scores?: a comparison of concordance between manual and computer‐based calculation of CHADS2 and CHA2DS2‐VASc scores
(Wiley, 2016-03-01)
[Abstract] BACKGROUND: Clinical risk scores, CHADS2 and CHA2 DS2 -VASc scores, are the established tools for assessing stroke risk in patients with atrial fibrillation (AF).
AIM: The aim of this study is to assess concordance ...
Prevalence of atrial fibrillation in Spain: OFRECE Study results
(Elsevier, 2013-11-23)
[Abstract] Introduction and objectives. Atrial fibrillation is associated with substantial morbidity and mortality and both its incidence and prevalence are high. Nevertheless, comprehensive data on this condition in Spain ...
Relation of quality of anticoagulation control with different management systems among patients with atrial fibrillation: data from FANTASIIA Registry
(Wiley, 2018-02-09)
[Abstract]
Background. Anticoagulation control in patients with atrial fibrillation (AF) has a multidisciplinary approach although is usually managed by general practitioners (GP) or haematologists. The aim of our study ...
Association of body mass index with clinical outcomes in patients with atrial fibrillation: a report from the FANTASIIA Registry
(NLM, 2019-12-24)
[Abstract]
Background.
Obesity and atrial fibrillation (AF) frequently coexist and independently increase mortality. We sought to assess the association between obesity and adverse events in patients receiving oral ...
Choice of new oral anticoagulant agents versus vitamin K antagonists in atrial fibrillation: FANTASIIA study
(SAGE, 2015-07-30)
[Abstract] Introduction: Atrial fibrillation (AF) is associated with an increased risk of thromboembolic events. Many patients with AF receive chronic anticoagulation, either with vitamin K antagonists (VKAs) or with non-VKA ...